These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 29359764)

  • 1. Structure-based inhibitors of tau aggregation.
    Seidler PM; Boyer DR; Rodriguez JA; Sawaya MR; Cascio D; Murray K; Gonen T; Eisenberg DS
    Nat Chem; 2018 Feb; 10(2):170-176. PubMed ID: 29359764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based inhibitors halt prion-like seeding by Alzheimer's disease-and tauopathy-derived brain tissue samples.
    Seidler PM; Boyer DR; Murray KA; Yang TP; Bentzel M; Sawaya MR; Rosenberg G; Cascio D; Williams CK; Newell KL; Ghetti B; DeTure MA; Dickson DW; Vinters HV; Eisenberg DS
    J Biol Chem; 2019 Nov; 294(44):16451-16464. PubMed ID: 31537646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 31-residue peptide induces aggregation of tau's microtubule-binding region in cells.
    Stöhr J; Wu H; Nick M; Wu Y; Bhate M; Condello C; Johnson N; Rodgers J; Lemmin T; Acharya S; Becker J; Robinson K; Kelly MJS; Gai F; Stubbs G; Prusiner SB; DeGrado WF
    Nat Chem; 2017 Sep; 9(9):874-881. PubMed ID: 28837163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformation determines the seeding potencies of native and recombinant Tau aggregates.
    Falcon B; Cavallini A; Angers R; Glover S; Murray TK; Barnham L; Jackson S; O'Neill MJ; Isaacs AM; Hutton ML; Szekeres PG; Goedert M; Bose S
    J Biol Chem; 2015 Jan; 290(2):1049-65. PubMed ID: 25406315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural study of the recognition mechanism of tau antibody Tau2r3 with the key sequence (VQIINK) in tau aggregation.
    Tsuchida T; Susa K; Kibiki T; Tsuchiya T; Miyamoto K; In Y; Minoura K; Taniguchi T; Ishida T; Tomoo K
    Biochem Biophys Res Commun; 2021 Dec; 585():36-41. PubMed ID: 34784549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tau amyloid formation and disruption of its preformed fibrils by Naphthoquinone-Dopamine hybrid.
    Paul A; Viswanathan GK; Huber A; Arad E; Engel H; Jelinek R; Gazit E; Segal D
    FEBS J; 2021 Jul; 288(14):4267-4290. PubMed ID: 33523571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating in vitro and in silico approaches to evaluate the "dual functionality" of palmatine chloride in inhibiting and disassembling Tau-derived VQIVYK peptide fibrils.
    Haj E; Losev Y; Guru KrishnaKumar V; Pichinuk E; Engel H; Raveh A; Gazit E; Segal D
    Biochim Biophys Acta Gen Subj; 2018 Jul; 1862(7):1565-1575. PubMed ID: 29634991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau R2 and R3 are essential regions for tau aggregation, seeding and propagation.
    Annadurai N; Malina L; Malohlava J; Hajdúch M; Das V
    Biochimie; 2022 Sep; 200():79-86. PubMed ID: 35623497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tau domain-specific antibodies and intravenous immunoglobulin on tau aggregation and aggregate degradation.
    Esteves-Villanueva JO; Trzeciakiewicz H; Loeffler DA; Martić S
    Biochemistry; 2015 Jan; 54(2):293-302. PubMed ID: 25545358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic insights into remodeled Tau-derived PHF6 peptide fibrils by Naphthoquinone-Tryptophan hybrids.
    KrishnaKumar VG; Paul A; Gazit E; Segal D
    Sci Rep; 2018 Jan; 8(1):71. PubMed ID: 29311706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cellular polyanion mimetics on tau peptide aggregation.
    Ismail T; Kanapathipillai M
    J Pept Sci; 2018 Nov; 24(11):e3125. PubMed ID: 30251388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of size distribution and (Pro249-Ser258) epitope exposure in in vitro and in vivo derived Tau fibrils.
    Marreiro A; Van Kolen K; Sousa C; Temmerman L; Vasconcelos B; Crespo-Rodriguez R; van Weering JRT; Van Dam D; De Deyn PP; Apetri A; Schoofs L; Mercken MH
    BMC Mol Cell Biol; 2020 Nov; 21(1):81. PubMed ID: 33183222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau peptides and tau mutant protein aggregation inhibition by cationic polyethyleneimine and polyarginine.
    Nadimidla K; Ismail T; Kanapathipillai M
    Biopolymers; 2017 Sep; 107(9):. PubMed ID: 28456996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent Tau Aggregation Inhibitor D-Peptides Selected against Tau-Repeat 2 Using Mirror Image Phage Display.
    Malhis M; Kaniyappan S; Aillaud I; Chandupatla RR; Ramirez LM; Zweckstetter M; Horn AHC; Mandelkow E; Sticht H; Funke SA
    Chembiochem; 2021 Nov; 22(21):3049-3059. PubMed ID: 34375027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of tau aggregation using a naturally-occurring cyclic peptide scaffold.
    Wang CK; Northfield SE; Huang YH; Ramos MC; Craik DJ
    Eur J Med Chem; 2016 Feb; 109():342-9. PubMed ID: 26807864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inert and seed-competent tau monomers suggest structural origins of aggregation.
    Mirbaha H; Chen D; Morazova OA; Ruff KM; Sharma AM; Liu X; Goodarzi M; Pappu RV; Colby DW; Mirzaei H; Joachimiak LA; Diamond MI
    Elife; 2018 Jul; 7():. PubMed ID: 29988016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can any "non-specific charge modification within microtubule binding domains of Tau" be a prerequisite of the protein amyloid aggregation? An in vitro study on the 1N4R isoform.
    Jangholi A; Ashrafi-Kooshk MR; Arab SS; Karima S; Poorebrahim M; Ghadami SA; Moosavi-Movahedi AA; Khodarahmi R
    Int J Biol Macromol; 2018 Apr; 109():188-204. PubMed ID: 29248553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the disrupting mechanism of the Tau aggregation motif "
    Moreno-Castillo E; Álvarez-Ginarte YM; Valdés-Tresanco ME; Montero-Cabrera LA; Moreno E; Valiente PA
    J Mol Recognit; 2020 Sep; 33(9):e2848. PubMed ID: 32227525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease.
    Harrington CR; Storey JM; Clunas S; Harrington KA; Horsley D; Ishaq A; Kemp SJ; Larch CP; Marshall C; Nicoll SL; Rickard JE; Simpson M; Sinclair JP; Storey LJ; Wischik CM
    J Biol Chem; 2015 Apr; 290(17):10862-75. PubMed ID: 25759392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De novo designed protein inhibitors of amyloid aggregation and seeding.
    Murray KA; Hu CJ; Griner SL; Pan H; Bowler JT; Abskharon R; Rosenberg GM; Cheng X; Seidler PM; Eisenberg DS
    Proc Natl Acad Sci U S A; 2022 Aug; 119(34):e2206240119. PubMed ID: 35969734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.